Psoriasis induced by dupilumab therapy

Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab

“…Our case represents one of the few reported clinical cases of psoriasis arising during dupilumab therapy in the literature 3‐5. To our knowledge, no cases of psoriasis, either new presentation or exacerbation, were recorded during preliminary studies of dupilumab.…”

Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series

“…Furthermore, the treatment of psoriasis with anti‐interleukin 17 agents may induce eczematous reactions (Napolitano et al, ). Similarly, IL‐4 and IL‐13 blockade by dupilumab could induce a shift toward Th1/Th17 subsets, leading to psoriasis (Safa & Paumier, ). It has been highlighted that IL‐4 downregulates Th1 and Th17 cells and, can modulate dendritic cells thus suppressing IL‐23 production.…”

“…However, no data regarding the anamnesis of psoriasis were reported (Gori et al, ; Tracey et al, ). Safa et al described a 55‐year‐old man affected by AD without a personal or family history of psoriasis who presented with erythematous and scaly plaques affecting the trunk after 2 months of treatment with dupilumab, which was resolved after a short therapy with a potent topical steroid without the need to discontinue dupilumab (Safa & Paumier, ). Only 1 of 3 our patients needed to interrupt the treatment with dupilumab; he had a family history of psoriasis.…”

“…It has been highlighted that IL-4 downregulates Th1 and Th17 cells and, can modulate dendritic cells thus suppressing IL-23 production. In addition, it can inhibit the secretion of epidermal IL-1b and IL-6 from psoriatic plaques (Hahn & Ghoreschi, 2017;Safa & Paumier, 2019). A case of erythrodermic psoriasis (Tracey et al, 2018) and a case of guttate psoriasis (Gori, Caldarola, Pirro, De Simone, & Peris, 2019) during treatment with dupilumab have been reported.…”

A case of guttate psoriasis during treatment with dupilumab

“…In our patient, guttate psoriasis, which developed 16 weeks after initiation of dupilumab treatment, may suggest the presence of a not yet identified infectious trigger exacerbating psoriasis. However, a triggering role of dupilumab in the development of psoriasis may not be ruled out, To date, two similar case reports have already been published (Safa, 2019;Tracey, 2018). Recently, Tracey et al described one patient affected by mild psoriasis and severe AD, who developed erythrodermic psoriasis during treatment with dupilumab.…”